{"id":391192,"date":"2015-12-23T00:00:00","date_gmt":"2015-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorim0415-biopharma-psoriasis-pharmacor-g7-2015\/"},"modified":"2026-03-31T09:02:31","modified_gmt":"2026-03-31T09:02:31","slug":"pcorim0415-biopharma-psoriasis-pharmacor-g7-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorim0415-biopharma-psoriasis-pharmacor-g7-2015\/","title":{"rendered":"Psoriasis | Pharmacor | G7 | 2015"},"content":{"rendered":"<p><em>Last Updated 23 December 2015<\/em><br \/>\nThe psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor-alpha (TNF-\u03b1) inhibitors is being challenged by the\u00a0interleukin-12\u00a0and 23 (IL-12\/23) inhibitor, ustekinumab (Janssen Biotech\u2019s Stelara), and more recently, by the introduction of Novartis\u2019s IL-17 inhibitor, secukinumab (Cosentyx), and Celgene\u2019s oral phosphodiesterase-4 (PDE4) inhibitor,\u00a0apremilast (Otezla). Novel oral therapies are generating interest following the remarkable uptake of\u00a0Otezla\u00a0in the first year of its launch. Thus, opportunities exist for developing safer and more-efficacious treatments in different drug classes for psoriasis; however, emerging therapies will have to deal with growing cost constraints and an increasingly competitive market. Additionally, the landscape will change further once biosimilars of frequently prescribed\u00a0TNF-alpha inhibitors\u00a0for psoriasis arrive in the major markets.<\/p>\n","protected":false},"template":"","class_list":["post-391192","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391192\/revisions"}],"predecessor-version":[{"id":394315,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391192\/revisions\/394315"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}